AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model - Wikidata - wikimedia - TriplyDB

AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model

AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model

http://www.wikidata.org/entity/Q34248473

about

Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation Prospects for gene transfer for clinical heart failure GRK2 in the heart: a GPCR kinase and beyond Cardiovascular gene therapy for myocardial infarction Allogeneic cardiospheres delivered via percutaneous transendocardial injection increase viable myocardium, decrease scar size, and attenuate cardiac dilatation in porcine ischemic cardiomyopathy Structural and Functional Analysis of G Protein-Coupled Receptor Kinase Inhibition by Paroxetine and a Rationally Designed Analog "Freeze, Don't Move": How to Arrest a Suspect in Heart Failure - A Review on Available GRK2 Inhibitors Adeno-associated virus-mediated gene therapy in cardiovascular disease The expanding GRK interactome: Implications in cardiovascular disease and potential for therapeutic development.Gene therapy delivery systems for enhancing viral and nonviral vectors for cardiac diseases: current concepts and future applications.The role of G protein coupled receptor kinases in neurocardiovascular pathophysiology The potential of adeno-associated viral vectors for gene delivery to muscle tissue.Identification and structure-function analysis of subfamily selective G protein-coupled receptor kinase inhibitors Molecular basis for small molecule inhibition of G protein-coupled receptor kinases Methods to improve cardiac gene therapy expression.Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors.The evolving impact of g protein-coupled receptor kinases in cardiac health and disease Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine.Comparison of adeno-associated virus serotypes and delivery methods for cardiac gene transfer.Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction Myocardial pathology induced by aldosterone is dependent on non-canonical activities of G protein-coupled receptor kinases.Gene transfer for congestive heart failure: update 2013.Cardiac Fibrosis: The Fibroblast Awakens AAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility.Prognostic Value of Lymphocyte G Protein-Coupled Receptor Kinase-2 Protein Levels in Patients With Heart Failure GRK2 in Lymphocytes: Expanding the Arsenal of Heart Failure Prognostics.GRK 2 level in peripheral blood lymphocytes of elderly patients with acute myocardial infarction A peptide of the RGS domain of GRK2 binds and inhibits Gα(q) to suppress pathological cardiac hypertrophy and dysfunction.An emerging adeno-associated viral vector pipeline for cardiac gene therapy Adrenergic nervous system in heart failure: pathophysiology and therapy.Structural insights into G protein-coupled receptor kinase function.Cardiac progenitor cells engineered with βARKct have enhanced β-adrenergic tolerance.Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium.Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapy G protein-coupled receptor kinase 2 promotes cardiac hypertrophy β-adrenergic receptor signalling and its functional consequences in the diseased heart.From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure Integrating GRK2 and NFkappaB in the Pathophysiology of Cardiac Hypertrophy.Neurohormonal activation in heart failure with reduced ejection fraction.GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease.

P2860

Q26799437-90665CE8-C7D4-405C-8A6B-E10C4D83FD6F Q26830145-620CB515-5438-42E4-BFF3-0537430D5047 Q26851548-8AF4485C-131C-4811-9698-9009B53E2500 Q27014770-C965E5A5-70AB-4207-AB25-CE943C88CD16 Q27322954-B5CCBDB5-67FE-465B-8E44-D2077E90C282 Q27680587-D4BBEBC2-56CC-4A88-9ECA-2E31AD7417E5 Q28078766-B6D48F80-A8BD-4549-B4D2-5B99B7C38D0B Q28081681-E93D029D-9607-4559-A95B-0DB3C7176662 Q30250314-932D303A-80F9-4441-9F16-297B0C671A2A Q30427066-66A43EF8-AB3B-4E5E-B7B4-4ECE8B11C154 Q30459130-102AD757-DA35-4C47-B01D-398BA90CDBAB Q33902499-16938C5E-4D22-4166-8916-4A4408FB04DF Q34992323-E14E80F4-7DE6-4551-99FA-9559105B8A55 Q34992803-F7936F6B-CD99-4F08-B2C3-089A3ACE0391 Q35360600-11773661-1D22-42C3-AF22-8D87DE1A8489 Q35981205-B9334601-038C-46CC-9BBE-CCC0DD26A6A6 Q36000382-CD3EB902-103B-40D5-AF75-68BAE94904AC Q36316194-B5613B8A-DC7A-4804-ABA7-A70E7FEC0F21 Q36563927-0F1CC5E6-C1D4-42A2-A4B7-9EB05B681112 Q36623426-CB1DABAF-5908-44E6-B752-598B26DCCCCE Q36651023-D4614E6E-24D1-4399-B90F-E40C8780E3CD Q36698991-8AD7C182-9A02-4D29-817C-CE1712230885 Q36708340-CBC002F9-0A93-4535-9049-442B7B8E11B0 Q36756838-C9FA85E1-B6EA-4C87-B379-08B318CA9D11 Q36757784-081F9C6A-6960-4A75-BE08-BD0CEE906226 Q36760778-FF507EE3-0EAB-4DEC-BE19-9AAD986E3452 Q37229933-85752FD9-4F3E-42F5-B145-9660889FBAEB Q37241927-E34302D4-8514-4D44-AAE8-2AD4C09213F8 Q37272838-267B37DF-1574-40D7-BB98-349C6D411218 Q37349756-9EC3399D-E455-4650-A8E5-33478E360213 Q37676935-0FD87F34-B354-4E80-943F-C1C7C027C592 Q37690449-FC6F2012-3322-4F73-BC5D-40A832B221A0 Q38132253-BD38B12F-4E6F-4BCA-9758-406191D1AD10 Q38153376-63F8B6C1-39AE-4AF5-94FF-699FFB64DDBB Q38651555-A03F704A-E9AA-4583-B1B7-4199F3D280DB Q38722030-A492E483-DB16-4BC8-BB18-891CBBB35A68 Q38780801-10502137-77AC-4AEB-B7A0-797E1F958CBA Q38848001-8EB4160D-52A3-4000-ADEC-1DD8A5C21F7E Q38973209-C9FDE441-E21E-4C63-97E0-648F7440FB93 Q39080324-E07C524A-0CC0-4087-B819-DFA778492F55

P2860

AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model

http://www.wikidata.org/entity/Q34248473

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

AAV6.βARKct cardiac gene thera ...... rge animal heart failure model

@ast

AAV6.βARKct cardiac gene thera ...... rge animal heart failure model

@en

AAV6.βARKct cardiac gene thera ...... rge animal heart failure model

@nl

type

label

AAV6.βARKct cardiac gene thera ...... rge animal heart failure model

@ast

AAV6.βARKct cardiac gene thera ...... rge animal heart failure model

@en

AAV6.βARKct cardiac gene thera ...... rge animal heart failure model

@nl

prefLabel

AAV6.βARKct cardiac gene thera ...... rge animal heart failure model

@ast

AAV6.βARKct cardiac gene thera ...... rge animal heart failure model

@en

AAV6.βARKct cardiac gene thera ...... rge animal heart failure model

@nl

P1433

Q34248473-CB10C9E3-B13C-4EC1-B8BA-877F1C749EAA

P1476

Q34248473-D380D4B8-F568-48E5-825D-1C41C9F916A7

P2093

Q34248473-073A75C9-E032-46DD-9DC2-D4631EF0E21B

Q34248473-444E922E-5533-4F47-A7E6-372A14FBA1AE

Q34248473-5C556338-9610-4906-AFF5-974FAA27A12B

Q34248473-787C25C7-CBEB-4E0F-8155-0FC9E5168C91

Q34248473-89C4A39B-552B-42CD-9ED3-036A1F616703

Q34248473-98ED809C-D5C2-47DB-8A2A-E51BC171D40A

Q34248473-AB32A98E-D1C5-4740-BCCE-186A9CA93165

Q34248473-B7F09CAF-C6D1-4F82-BD59-4FAE59D7A8D8

Q34248473-D4F57850-5F96-470D-9264-82526C31B4F2

Q34248473-DCA41631-B9A0-4613-A962-BFC3C6ED5733

P2860

Q34248473-01FF324F-F385-4041-B947-28D06DBCC6DA

Q34248473-0CB2D554-6909-453B-A4D2-5B53230275B4

Q34248473-14EDDB39-84C7-43FB-93E6-A99FF5991BF7

Q34248473-41679981-777C-43CF-A8AE-9F3E5D571513

Q34248473-46304A9B-7819-4266-9550-69BF559AB9AA

Q34248473-531C0050-0C7E-4EE4-99AD-842EA7A59680

Q34248473-5DD65F69-33FF-48C1-A65D-C9C81E311048

Q34248473-63EFE036-95B7-4B20-9F3E-584691E60683

Q34248473-77F0C3A4-0EA8-4F4D-88E3-D99C518D92A0

Q34248473-819504B0-8F00-4864-B45A-EB37FFED6283

P304

Q34248473-6F636F36-6AA4-4411-B7AA-EEC933615F64

P31

Q34248473-8C82F644-1C69-4635-89C6-79411BA82C7F

P356

Q34248473-CA942468-3462-4A8B-912C-8424B31D6B53

P433

Q34248473-0F26A78E-1E14-4AC1-8AF7-0BCECF447104

P478

Q34248473-6FBF66A3-9487-46B9-8794-A164275AF048

P50

Q34248473-E41D3CAA-3731-4AD2-A596-5CBFB52A77F3

P577

Q34248473-70DD112E-0CDF-4718-8C30-AE0C27B83909

P5875

Q34248473-3A266C72-454D-4392-BAFF-4B2F91D58E31

P698

Q34248473-B33E1D69-E585-474E-82EA-F90CC81EBFF7

P921

Q34248473-2454D1F3-6B6D-420D-B1E6-9E3C1EC74702

Q34248473-A87466BF-1601-47EC-AFB8-D7BC176F5BDE

P932

Q34248473-CF7BA357-A597-4825-9C67-72BF4DD16C44

P356

P1433

European Heart Journal

P1476

AAV6.βARKct cardiac gene thera ...... rge animal heart failure model

@en

P2093

Hugo A Katus

http://www.w3.org/2001/XMLSchema#string

Jan Ksienzyk

http://www.w3.org/2001/XMLSchema#string

Jens Barthelmes

http://www.w3.org/2001/XMLSchema#string

Julia Reinkober

http://www.w3.org/2001/XMLSchema#string

Oliver J Müller

http://www.w3.org/2001/XMLSchema#string

Patrick Most

http://www.w3.org/2001/XMLSchema#string

Philip W J Raake

http://www.w3.org/2001/XMLSchema#string

Philipp Schlegel

http://www.w3.org/2001/XMLSchema#string

Stefanie Schinkel

http://www.w3.org/2001/XMLSchema#string

Sven Pleger

http://www.w3.org/2001/XMLSchema#string

P2860

Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure

Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice

Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction

Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model

Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure

Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor

G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure.

The inotropic peptide βARKct improves βAR responsiveness in normal and failing cardiomyocytes through G(βγ)-mediated L-type calcium current disinhibition.

Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group.

In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction.

P304

1437-1447

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHR447

http://www.w3.org/2001/XMLSchema#string

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221763445

http://www.w3.org/2001/XMLSchema#string

P698

22261894

http://www.w3.org/2001/XMLSchema#string

P921

P932

3653122

http://www.w3.org/2001/XMLSchema#string